本文關(guān)鍵詞： 肝細胞癌 肝外轉(zhuǎn)移 微陣列比較基因組雜交 拷貝數(shù)變異　出處：《安徽醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的肝細胞癌(hepatocellular carcinoma,HCC)是國內(nèi)常見的惡性腫瘤,手術(shù)仍是目前HCC的主要根治性治療方法,而術(shù)后肝外轉(zhuǎn)移是患者預(yù)后差的一個重要因素。但目前對于具有何種分子特征的HCC易發(fā)生肝外轉(zhuǎn)移仍知之甚少,因此篩選HCC術(shù)后肝外轉(zhuǎn)移相關(guān)分子標志具有重要意義。既往研究顯示DNA拷貝數(shù)變異(copy number aberrations,CNAs)與多種腫瘤進展和預(yù)后有關(guān),且與HCC術(shù)后肝內(nèi)復(fù)發(fā)相關(guān),但CNAs與HCC術(shù)后遠處轉(zhuǎn)移的關(guān)系仍不清楚。本研究旨在探討HCC術(shù)后肝外轉(zhuǎn)移相關(guān)的CNAs分子標志。方法以66例HCC術(shù)后患者為研究對象,隨訪首次出現(xiàn)肝外轉(zhuǎn)移的時間,無肝外轉(zhuǎn)移生存時間定義為手術(shù)至出現(xiàn)肝外轉(zhuǎn)移或末次隨訪之時間間隔。采用高分辨率Agilent 244K微陣列比較基因組雜交(array-based comparative genomic hybridization,a CGH)技術(shù)檢測HCC組織基因組DNA的CNAs。采用Agilent G2565BA DNA微陣列掃描儀對雜交芯片進行掃描,運用Feature Extraction v9.5進行數(shù)據(jù)提取與分析。全基因組CNAs與HCC術(shù)后遠處轉(zhuǎn)移的相關(guān)性分析采用Cox風(fēng)險比例模型和Log-rank檢驗,以Kaplan-Meier繪制生存曲線。P0.05為差異有統(tǒng)計學(xué)意義。統(tǒng)計學(xué)分析采用Stata 13.0統(tǒng)計學(xué)軟件包(Stata Corporation,College Station,TX)。結(jié)果1.全組66例HCC樣本的術(shù)后隨訪時間為1.6~90.5個月,中位隨訪時間39.9個月,總隨訪時間2633.4人月,隨訪期間共有25例(37.9%)患者出現(xiàn)肝外轉(zhuǎn)移。2.單因素Cox分析顯示,5個臨床病理學(xué)因素與HCC術(shù)后肝外轉(zhuǎn)移顯著相關(guān)(均P0.05),其中高血壓史、無完整腫瘤包膜、高TNM分期(Ⅲ期)為危險因素,而低血小板計數(shù)(100×109/L)和凝血酶原時間延長(12秒)為保護因素。3.全基因組CNAs與HCC術(shù)后遠處轉(zhuǎn)移的單因素Cox分析顯示,5個CNAs片段是肝外轉(zhuǎn)移的顯著相關(guān)因素(均P0.05),其中6p21.32增益、15q11.2增益和20q12-13.13增益是HCC術(shù)后肝外轉(zhuǎn)移的危險因素;4q12丟失和4q28.1-35.2丟失是轉(zhuǎn)移保護因素。4.HCC術(shù)后肝外轉(zhuǎn)移相關(guān)因素的多元逐步Cox回歸分析結(jié)果顯示,6p21.32增益、4q28.1-4q35.2缺失、高TNM分期(Ⅲ期)和高血壓史是HCC術(shù)后遠處轉(zhuǎn)移的獨立預(yù)后因素(均P0.05),其中6p21.32增益、高TNM分期和高血壓史是轉(zhuǎn)移危險因素,而4q28.1-4q35.2缺失是轉(zhuǎn)移保護因素。5.CNAs組合與HCC術(shù)后肝外轉(zhuǎn)移的相關(guān)性:依據(jù)6p21.32增益與4q28.1-35.2丟失狀態(tài)優(yōu)化組合,發(fā)現(xiàn)6p21.32增益、6p21.32無增益/4q28.1-35.2丟失和6p21.32無增益/4q28.1-35.2無丟失3組HCC的術(shù)后無肝外轉(zhuǎn)移生存差異有統(tǒng)計學(xué)意義(Log-rank檢驗,P0.01);相比6p21.32無增益/4q28.1-35.2無丟失組,6p21.32無增益/4q28.1-35.2丟失組的肝外轉(zhuǎn)移風(fēng)險顯著降低至0.18倍(95%CI=0.06~0.57,P0.01),而6p21.32增益組的肝外轉(zhuǎn)移風(fēng)險顯著增加至2.91倍(95%CI=1.13~7.46,P0.05)。結(jié)論1.6p21.32增益、15q11.2增益和20q12-13.13增益是HCC術(shù)后肝外轉(zhuǎn)移的危險因素,而4q12丟失和4q28.1-35.2丟失是轉(zhuǎn)移保護因素。2.6p21.32增益和4q28.1-35.2丟失是HCC術(shù)后肝外轉(zhuǎn)移的獨立預(yù)后因素,前者是轉(zhuǎn)移危險因素,后者是轉(zhuǎn)移保護因素。3.基于6p21.32增益和4q28.1-35.2丟失2個獨立預(yù)后因素的CNAs優(yōu)化組合可在手術(shù)早期對HCC術(shù)后肝外轉(zhuǎn)移風(fēng)險作出預(yù)判,從而為臨床治療決策提供依據(jù)。
[Abstract]:Objective hepatocellular carcinoma (hepatocellular, carcinoma, HCC) is a common malignant tumor in China, surgery is still the main HCC radical treatment methods, and postoperative liver metastasis is an important factor of poor prognosis. But for what is the molecular characteristics of HCC susceptible to extrahepatic metastasis remains poorly understood. The screening of HCC postoperative extrahepatic metastasis related molecular markers is important. Previous studies have shown that the copy number variation of DNA (copy number aberrations, CNAs) associated with the progression and prognosis of various tumors, and is associated with intrahepatic recurrence after HCC, but the relationship between CNAs and metastasis after HCC remains unclear. The purpose of this study is to to investigate the HCC postoperative extrahepatic metastasis CNAs molecular marker related. Methods 66 cases of HCC patients were followed up for the first time as the research object, extrahepatic metastasis, extrahepatic metastasis survival time is defined as to the liver surgery. Shift or last follow-up time interval. By using high resolution Agilent 244K microarray comparative genomic hybridization (array-based comparative genomic hybridization, a CGH DNA HCC) in detecting genomic organization technology using CNAs. Agilent G2565BA DNA microarray scanner on hybrid chip scan, using Feature Extraction v9.5 data extraction and analysis of genomic CNAs and correlation analysis. After HCC of distant metastasis with Cox proportional hazard model and Log-rank test, Kaplan-Meier.P0.05 to draw survival curves for significant difference. Statistical analysis using Stata 13 statistical software package (Stata Corporation, College Station, TX). All 66 cases were followed up for 1. HCC sample results after operation for 1.6~90.5 months. After a median follow-up of 39.9 months, the total follow-up time of 2633.4 months follow-up period, a total of 25 cases (37.9%) patients with liver. Shift.2. Cox univariate analysis showed that 5 factors of clinical pathology and HCC postoperative extrahepatic metastasis was significantly correlated (P0.05), the history of hypertension, no intact tumor capsule, high TNM stage (stage III) as a risk factor, and low platelet count (100 x 109/L) and prothrombin time (12 a second) appear as single factors of distant metastasis protective factors of.3. genomic CNAs and HCC after Cox analysis, 5 CNAs fragments were significantly related with extrahepatic metastasis (P0.05), the 6p21.32 gain, 15q11.2 gain and 20q12-13.13 gain are risk factors of HCC postoperative extrahepatic metastasis; 4q12 loss and 4q28.1-35.2 loss multiple factors related to transfer of protective factors of.4.HCC postoperative extrahepatic metastasis by Cox regression analysis showed that the 6p21.32 gain, 4q28.1-4q35.2 loss, high TNM stage (stage III) and history of hypertension is an independent prognostic factor for distant metastasis after HCC (P0.05), of which 6 P21.32 high gain, TNM staging and history of hypertension were the risk factors of metastasis, metastasis and 4q28.1-4q35.2 deletion is a protective factor for.5.CNAs in combination with HCC postoperative extrahepatic metastasis: Based on the 6p21.32 gain and 4q28.1-35.2 lost state optimization, 6p21.32 gain, 6p21.32 no gain without liver loss of /4q28.1-35.2 and 6p21.32 gain /4q28.1-35.2 without loss of 3 HCC the postoperative metastasis survival difference was statistically significant (Log-rank, P0.01); no gain no loss compared to 6p21.32 /4q28.1-35.2 group, 6p21.32 /4q28.1-35.2 group of liver abversion gain loss risk shift significantly reduced to 0.18 times (95%CI=0.06~0.57, P0.01), and the risk of 6p21.32 gain group extrahepatic metastasis significantly increased to 2.91 times (95%CI=1.13~7.46, P0.05). Conclusion 1.6p21.32 gain, 15q11.2 gain and 20q12-13.13 gain are risk factors of HCC postoperative extrahepatic metastasis, and loss of 4q12 and 4q28.1-35. 2 transfer loss is a protective factor for.2.6p21.32 gain and loss of 4q28.1-35.2 were independent prognostic factors of HCC postoperative extrahepatic metastasis, the former is the transfer of risk factors, the latter is the transfer of protective factors.3. optimization can be in operation early on HCC postoperative extrahepatic metastasis risk to predict CNAs 6p21.32 gain and 4q28.1-35.2 lost 2 independent prognostic factors based on, so as to provide the basis for clinical decision making.

【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R735.7

【參考文獻】

相關(guān)期刊論文 前10條

1 康雅芳;孫蓬明;;拷貝數(shù)變異在婦科惡性腫瘤中的研究進展[J];國際婦產(chǎn)科學(xué)雜志;2016年05期

2 楊菲;曹鵬博;周鋼橋;;常見拷貝數(shù)變異與疾病的關(guān)聯(lián)研究[J];中華醫(yī)學(xué)遺傳學(xué)雜志;2016年03期

3 李軻宇;劉連新;尹大龍;;肝細胞癌外科治療方式的研究進展[J];中華外科雜志;2016年02期

4 聞炳基;賀松琴;葉映泉;叢文銘;艾婷婷;余慈波;朱忠政;;肝細胞癌患者術(shù)后復(fù)發(fā)相關(guān)的6號染色體短臂拷貝數(shù)變異及靶基因[J];中華肝膽外科雜志;2015年12期

5 張靜;聞炳基;叢文銘;陳律;江軍;潘慰;何佳佳;朱忠政;;染色體17q區(qū)拷貝數(shù)變異與肝細胞癌總生存的相關(guān)性及靶基因的篩選[J];中華醫(yī)學(xué)遺傳學(xué)雜志;2015年05期

6 賀松琴;叢文銘;胡柳燕;嚴靜嫻;董輝;陳律;聞炳基;朱忠政;;4號染色體長臂拷貝數(shù)變異及復(fù)發(fā)表征基因與肝癌復(fù)發(fā)[J];中華實驗外科雜志;2015年10期

7 王美玲;姜斌;叢文銘;胡曉華;董輝;朱忠政;;染色體8p拷貝數(shù)變異與肝細胞癌術(shù)后總生存的關(guān)系及靶基因篩選[J];中華肝膽外科雜志;2015年05期

8 胡柳燕;艾婷婷;潘慰;何佳佳;嚴靜嫻;余慈波;聞炳基;王愛忠;朱忠政;;肝細胞癌術(shù)后肝外轉(zhuǎn)移的相關(guān)臨床病理學(xué)因素分析[J];現(xiàn)代實用醫(yī)學(xué);2015年05期

9 Yu Zhang;Zhi-Long Shi;Xia Yang;Zheng-Feng Yin;;Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis[J];World Journal of Gastroenterology;2014年01期

10 田景繪;唐艷霞;;非酒精性脂肪性肝病與原發(fā)性肝癌相關(guān)性探討[J];中國臨床新醫(yī)學(xué);2013年08期

，

本文編號：1550883